<DOC>
	<DOCNO>NCT02901106</DOCNO>
	<brief_summary>The dimethyl fumarate oral drug , indicate treatment relapsing-remitting multiple sclerosis ( MS ) , efficacy safety assess validate two randomise , placebo phase-controlled III international study , organize pharmaceutical company develop molecule . TECFIDERAÂ® ( dimethyl-fumarate ) receive European approval January 30 , 2014 , treatment adult patient relapse remit MS . Treatment dimethyl fumarate introduce part usual care supervision physician experience treatment disease . It prove effective reduce number relapse patient recurring-remitting MS reduce number patient relapse treatment . The objective study observe , real condition , one hand tolerance evolution , clinical radiologic disease patient already treat dimethyl-fumarate collect long-term safety data .</brief_summary>
	<brief_title>Monitoring Patients Followed Multiple Sclerosis Treated Dimethyl-fumarate</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>patient 18 year old multiple sclerosis accord criterion Mac Donald 2010 : relapsingremitting ( RR ) , secondaryprogressive ( SP ) primaryprogressive ( PP ) treatment dimethylfumarate prescribe follow Rothschild Foundation Neurology Department give write consent participation study pregnant breastfeed woman patient measure legal protection subject unaffiliated insurance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Multiple Sclerosis , Relapsing-Remitting</keyword>
	<keyword>Dimethyl fumarate</keyword>
</DOC>